stockrow
Friday 6 November 2026
Export CLYM’s income statement to Excel — free account
Climb Bio, Inc.
CLYM Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- +3.73%
Quarter to June 2026, against a year earlier
10.28
1.41
+15.90%
Follow CLYM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 | 1 | +7.4% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | (7) | (21) | (47) | (45) | (35) | (74) | (60) | (58) | +44.6% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (7) | (21) | (47) | (45) | (35) | (74) | (60) | (58) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.28) | (9.45) | (4.24) | (1.72) | (1.30) | (1.53) | (0.88) | (0.83) | +21.0% | ||||||
| Cash flow | — | — | — | (0.19) | (6.44) | (2.94) | (1.42) | (0.76) | (0.32) | (0.80) | (0.69) | +27.1% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | n/m | ||||||
| Free cash flow | — | — | — | (0.19) | (6.44) | (2.94) | (1.42) | (0.76) | (0.32) | (0.80) | (0.70) | +27.2% | ||||||
| Book value | — | — | — | 0.78 | (11.42) | 13.64 | 4.89 | 3.99 | 4.40 | 2.37 | 3.15 | +20.2% | ||||||
| Shares, m | — | — | — | 26 | 2 | 12 | 26 | 27 | 48 | 68 | 70 | +17.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (5) | (14) | (36) | (37) | (21) | (16) | (54) | (53) | +48.8% | |||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | 0 | — | ||||||
| Free cash flow | — | — | — | (5) | (14) | (36) | (37) | (21) | (16) | (55) | (53) | +48.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 21 | 19 | 142 | 128 | 107 | 150 | 99 | 181 | +30.0% | |||||
| Net debt | — | — | — | (21) | (20) | (136) | (124) | (107) | (151) | (101) | (183) | +29.7% | ||||||
| Shareholders’ equity | — | — | — | 21 | (25) | 167 | 129 | 108 | 212 | 160 | 240 | +40.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (69.09) | (99.74) | (52.59) | (29.36) | (28.61) | (45.11) | (31.10) | (26.27) | +38.0 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (72.57) | (547.86) | (3,142.56) | (84.09) | (71.43) | (71.73) | (71.4) pt | ||||||
| ROE | — | — | — | 48.39 | 150.29 | (73.17) | (30.58) | (29.72) | (46.26) | (32.15) | (27.10) | (80.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 25 | 31 | 43 | 11 | 18 | 28 | — | +2.3% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Climb Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ENTX Entera Bio Ltd. | $520.0M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | −108.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FTH Faeth Therapeutics, Inc. | $514.8M | — (loss-making) | — | — | n/m | −262.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NGNE Neurogene Inc. | $513.3M | — (loss-making) | — (loss-making) | — | n/m | −22.97% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLYM Climb Bio, Inc. | $509.5M | — (loss-making) | — | — | n/m | +3.73% (above 0%: growing) | — | 0.00% | |
| YDES YD Bio Limited | $508.7M | — | — | — | — | — | — | — | Compare |
| SLBT SL SCIENCE HLDG | $504.7M | — | — | — | — | — | — | — | Compare |
| PBYI Puma Biotechnology, Inc. | $504.3M | 15.3× | 24.2× | +7.75% (above 0%: growing) | +33.33% (above 0%: growing) | −88.45% (below 0%: shrinking) | 77.92% | 13.42% | Compare |
| OVID Ovid Therapeutics | $503.9M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | Compare |
| CAPR Capricor Therapeutics, Inc. | $500.0M | — (loss-making) | — (loss-making) | −7.92% (below 0%: shrinking) | n/m | −72.88% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $506.7M | — | — | +103.88% | — | −98.65% | 88.96% | 0.00% |
Pay and ownership Proxy statement filed 24 April 2026
Ownership
Directors and executive officers, together
2.60%
Entities affiliated with RA Capital
33.00%
Pontifax
10.90%
MPM BioImpact LLC
5.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement